Voxzogo was Biomarin Pharmaceutical’s largest product and service line in fiscal 2025, bringing in $926.92M of $3.22B (29%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Vimizim | $663.74M | $701.05M | $739.78M | $792.05M | ||||||
| Voxzogo | $169.13M | $469.88M | $735.09M | $926.92M | ||||||
| Naglazyme | $443.79M | $420.29M | $479.58M | $485.40M | ||||||
| Palynziq | $255.03M | $303.92M | $355.05M | $433.31M | ||||||
| Kuvan | $227.58M | $180.77M | $120.90M | $99.53M | ||||||
| Brineura | $154.33M | $161.89M | $169.08M | $186.40M | ||||||
| Aldurazyme | $128.42M | $131.25M | $183.89M | $208.51M | ||||||
| Aldurazyme Net Product Revenues Marketed By Sanofi | — | — | — | — | ||||||
| Royalty & Other Revenues | $54.01M | $46.69M | $44.47M | $53.49M | ||||||
| Roctavian | — | $3.49M | $26.07M | $35.64M | ||||||
| Firdapse | — | — | — | — | ||||||
| Total | $2.10B | $2.42B | $2.85B | $3.22B |
Biomarin Pharmaceutical brought in $3.22B from its nine product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 12.9% from $2.85B in fiscal 2024. Voxzogo was the largest at $926.92M (28.8%), ahead of Vimizim at $792.05M (24.6%) and Naglazyme at $485.40M (15.1%). The other six lines brought in $1.02B combined.
Compared with fiscal 2024, Voxzogo grew fastest, up 26.1% to $926.92M, while Kuvan fell the most, down 17.7% to $99.53M.
Biomarin Pharmaceutical began breaking out Roctavian in fiscal 2023, when it brought in $3.49M.
Marketed By Company was Biomarin Pharmaceutical’s largest revenue line in fiscal 2025, bringing in $2.96B of $3.17B (93%).
| Contract With Customer Sales Channel | FY 2016 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Marketed By Company | $2.24B | $2.63B | $2.96B | |
| Marketed By Sanofi | $131.25M | $183.89M | $208.51M | |
| Marketed By Genzyme | — | — | — | |
| Total | $2.37B | $2.81B | $3.17B |
Biomarin Pharmaceutical brought in $3.17B from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 12.8% from $2.81B in fiscal 2024. Marketed By Company was the largest at $2.96B (93.4%), ahead of Marketed By Sanofi at $208.51M (6.6%).
Compared with fiscal 2024, Marketed By Sanofi grew 13.4% to $208.51M and Marketed By Company grew 12.7% to $2.96B. From fiscal 2023 to 2025, combined revenue from these revenue lines grew from $2.37B to $3.17B, a compound annual growth rate of 15.5%. Marketed By Company's share of the total fell from 94.5% to 93.4%.
United States was Biomarin Pharmaceutical’s largest region in fiscal 2018, bringing in $696.79M of $1.49B (47%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|---|---|---|
| United States | $444.08M | $507.54M | $588.24M | $696.79M | |||
| Europe | $171.22M | $340.78M | $398.81M | $436.43M | |||
| Latin America | $142.31M | $147.47M | $181.97M | $185.05M | |||
| Rest Of World | $132.30M | $121.07M | $144.62M | $172.94M | |||
| Total | $889.90M | $1.12B | $1.31B | $1.49B |
Biomarin Pharmaceutical brought in $1.49B from its four regions in fiscal 2018, the year ended December 31, 2018. That was up 13.5% from $1.31B in fiscal 2017. United States was the largest at $696.79M (46.7%), ahead of Europe at $436.43M (29.3%) and Latin America at $185.05M (12.4%). The remaining region, Rest Of World, brought in $172.94M.
Compared with fiscal 2017, Rest Of World grew fastest, up 19.6% to $172.94M. Every region above 2% of revenue grew. From fiscal 2015 to 2018, combined revenue from these regions grew from $889.90M to $1.49B, a compound annual growth rate of 18.8%. United States' share of the total fell from 49.9% to 46.7%.
Biomarin Pharmaceutical (BMRN) reports its revenue by product and service, by contract with customer sales channel and by geography. In fiscal 2025, Voxzogo was its largest product and service line, bringing in $926.92M (28.8% of the total), followed by Vimizim at $792.05M (24.6%).
Voxzogo was Biomarin Pharmaceutical's largest product and service line in fiscal 2025, bringing in $926.92M, or 28.8% of the $3.22B total across its nine product and service lines.
Marketed By Company was Biomarin Pharmaceutical's largest revenue line in fiscal 2025, bringing in $2.96B, or 93.4% of the $3.17B total across its two revenue lines.
United States was Biomarin Pharmaceutical's largest region in fiscal 2018, bringing in $696.79M, or 46.7% of the $1.49B total across its four regions.
Among Biomarin Pharmaceutical's product and service lines that make up at least 2% of revenue, Voxzogo grew fastest in fiscal 2025, up 26.1% from $735.09M to $926.92M.
Every figure comes from Biomarin Pharmaceutical's annual financial filings, as reported. Each line keeps the name Biomarin Pharmaceutical gives it, and years follow its fiscal calendar.
Biomarin Pharmaceutical's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.